289 related articles for article (PubMed ID: 16699873)
41. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials.
Ferreri AJ; Reni M; Villa E
Ann Oncol; 2000 Aug; 11(8):927-37. PubMed ID: 11038028
[TBL] [Abstract][Full Text] [Related]
42. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
43. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
44. Combined modality therapy for primary CNS lymphoma.
DeAngelis LM; Yahalom J; Thaler HT; Kher U
J Clin Oncol; 1992 Apr; 10(4):635-43. PubMed ID: 1548527
[TBL] [Abstract][Full Text] [Related]
45. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
Poortmans PM; Kluin-Nelemans HC; Haaxma-Reiche H; Van't Veer M; Hansen M; Soubeyran P; Taphoorn M; Thomas J; Van den Bent M; Fickers M; Van Imhoff G; Rozewicz C; Teodorovic I; van Glabbeke M;
J Clin Oncol; 2003 Dec; 21(24):4483-8. PubMed ID: 14597741
[TBL] [Abstract][Full Text] [Related]
46. Analysis of radiotherapy in 1054 patients with primary central nervous system lymphoma treated from 1985 to 2009.
Shibamoto Y; Sumi M; Takemoto M; Tsuchida E; Onodera S; Matsushita H; Sugie C; Tamaki Y; Onishi H
Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):653-60. PubMed ID: 25034088
[TBL] [Abstract][Full Text] [Related]
47. (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.
Collignon A; Houillier C; Ahle G; Chinot O; Choquet S; Schmitt A; Agape P; Soussain C; Hoang-Xuan K; Tabouret E
Ann Hematol; 2019 Apr; 98(4):915-922. PubMed ID: 30535802
[TBL] [Abstract][Full Text] [Related]
48. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy.
Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065
[TBL] [Abstract][Full Text] [Related]
49. High-dose methotrexate for elderly patients with primary CNS lymphoma.
Zhu JJ; Gerstner ER; Engler DA; Mrugala MM; Nugent W; Nierenberg K; Hochberg FH; Betensky RA; Batchelor TT
Neuro Oncol; 2009 Apr; 11(2):211-5. PubMed ID: 18757775
[TBL] [Abstract][Full Text] [Related]
50. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
51. Results of primary central nervous system lymphoma treated by radiation and chemotherapy: retrospective analysis of twelve institutions in the Tokai District of Japan, 1995-1999.
Kawamura T; Ishiguchi T; Shibamoto Y; Ogino H; Ishihara S; Yamada T; Katada K; Suzuki K; Suzuki H; Mimura M
Radiat Med; 2006 Jan; 24(1):9-16. PubMed ID: 16715656
[TBL] [Abstract][Full Text] [Related]
52. Characteristics and outcome of patients with primary CNS lymphoma in a "real-life" setting compared to a clinical trial.
Zeremski V; Koehler M; Fischer T; Schalk E
Ann Hematol; 2016 Apr; 95(5):793-9. PubMed ID: 26801791
[TBL] [Abstract][Full Text] [Related]
53. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
Hoang-Xuan K; Taillandier L; Chinot O; Soubeyran P; Bogdhan U; Hildebrand J; Frenay M; De Beule N; Delattre JY; Baron B;
J Clin Oncol; 2003 Jul; 21(14):2726-31. PubMed ID: 12860951
[TBL] [Abstract][Full Text] [Related]
54. Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma.
Seidel S; Pels H; Schlömer S; Kowoll A; Fliessbach K; Engert A; Vogt-Schaden M; Egerer G; Reichmann H; Schackert G; Kroschinsky F; Deckert M; Herrlinger U; Klockgether T; Fimmers R; Bode U; Schmidt-Wolf IGH; Schlegel U
Neurology; 2020 Dec; 95(23):e3138-e3144. PubMed ID: 32989105
[TBL] [Abstract][Full Text] [Related]
55. Outcome of patients with primary central nervous system lymphoma treated outside clinical trials.
Hart A; Baars JW; Kersten MJ; Brandsma D; van Tinteren H; de Jong D; Spiering M; Dewit L; Boogerd W
Neth J Med; 2014 May; 72(4):218-23. PubMed ID: 24829178
[TBL] [Abstract][Full Text] [Related]
56. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
57. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients.
Freilich RJ; Delattre JY; Monjour A; DeAngelis LM
Neurology; 1996 Feb; 46(2):435-9. PubMed ID: 8614508
[TBL] [Abstract][Full Text] [Related]
58. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
Fossard G; Ferlay C; Nicolas-Virelizier E; Rey P; Ducray F; Jouanneau E; Faurie P; Belhabri A; Sunyack MP; Chassagne-Clément C; Thiesse P; Sebban C; Biron P; Blay JY; Ghesquières H
Eur J Cancer; 2017 Feb; 72():12-19. PubMed ID: 28012348
[TBL] [Abstract][Full Text] [Related]
59. MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years.
Ferreri AJ; Ciceri F; Brandes AA; Montanari M; Balzarotti M; Spina M; Ilariucci F; Zaja F; Stelitano C; Bobbio F; Corazzelli G; Baldini L; Reni M
Neurology; 2014 Apr; 82(15):1370-3. PubMed ID: 24634458
[TBL] [Abstract][Full Text] [Related]
60. Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis.
Prica A; Chan K; Cheung MC
Br J Haematol; 2012 Sep; 158(5):600-7. PubMed ID: 22734565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
